![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Dolutegravir Regimen Statistically Superior to Efavirenz/Tenofovir/Emtricitabine:
96-Week Results From the SINGLE Study (ING114467)
|
|
|
Reported by Jules Levin
CROI 2014 March 3-6 Boston, MA
S Walmsley1, J Berenguer2, M Khuong-Josses3, JM Kilby4, T Lutz5, D Podzamczer6, N Roth7, C Granier8, B Wynne9, K Pappa10
1University Health Network, Toronto, Canada; 2Hospital General Universitario Gregorio Maranon, Madrid, Spain; 3Hopital Delafontaine, Paris, France; 4Medical University of South Carolina, Charleston, SC; 5Infektiologikum Frankfurt, Frankfurt, Germany; 6Hospital Universitari de Bellvitge, L'Hospitalet, Barcelona, Spain; 7Prahran Market Clinic, Melbourne, Australia; 8-10GlaxoSmithKline, 8London, United Kingdom; 9Philadelphia, PA; 10Research Triangle Park, NC
delphia, PA; 10Research Triangle Park, NC
![CROI1.gif](../images/031314/031314-4/CROI1.gif)
![CROI2.gif](../images/031314/031314-4/CROI2.gif)
![CROI3.gif](../images/031314/031314-4/CROI3.gif)
![CROI4.gif](../images/031314/031314-4/CROI4.gif)
![CROI5.gif](../images/031314/031314-4/CROI5.gif)
![CROI6.gif](../images/031314/031314-4/CROI6.gif)
![CROI7.gif](../images/031314/031314-4/CROI7.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|